Latest News
Intelligent Bio Solutions Highlights Continued Expansion with Strategic Partnership in Spain and Andorra
INBS set to capitalize on growing Spanish Drug Testing Market, anticipated to reach $448 million by 2030 Major Spanish accounts
Intelligent Bio Solutions Secures Key U.S. Patent, Strengthening IP Protection Ahead of Planned 2025 Market Entry
Company’s 6th U.S. patent adds to comprehensive IP portfolio protecting its unique drug screening technology Patent protection strengthens Company’s competitive
Intelligent Bio Solutions’ FDA Clearance Process Remains on Track for 2025 U.S. Launch
NEW YORK, March 25, 2025 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering